Result of AGM

RNS Number : 1111Y
Hikma Pharmaceuticals Plc
12 May 2016
 

 

Hikma Pharmaceuticals PLC

Voting Results of 2016 Annual General Meeting

LONDON, 12 May 2016 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at The Westbury, Bond Street, Mayfair, London W1S 2YF on 12 May 2016 commenced at 11:00 am today. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 16 were passed as ordinary resolutions and Resolutions 17 to 19 were passed as special resolutions.

As previously announced, Mr. Breffni Byrne retired from the Board at the close of the AGM.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the UK Listing Authority for publication through the Listing Authority's Document Viewing Facility. 

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 7 April 2016). is set out below. The number of Ordinary Shares in issue on 12 May 2016 was 239,385,501.

  

Resolution

Votes For

%

Votes Against

%

Votes Withheld

1

To receive the 2015 report and accounts

201,043,426

99.83%

347,462

0.17%

197,375

2

To approve a final dividend of 21 cents per share

201,588,263

100.00%

0

0.00%

0

3

Appoint PricewaterhouseCoopers LLP as auditors

198,964,787

98.70%

2,623,476

1.30%

0

4

Authorise the Audit Committee to set the remuneration of the auditors

194,789,399

96.63%

6,798,864

3.37%

0

5

Appoint Jochen Gann

199,061,688

98.75%

2,526,551

1.25%

0

6

Appoint John Castellani

200,675,819

99.55%

912,421

0.45%

0

7

Reappointment of Said Darwazah

196,614,743

97.69%

4,641,117

2.31%

332,378

8

Reappointment of Mazen Darwazah

197,410,765

97.93%

4,177,474

2.07%

0

9

Reappointment of Robert Pickering

199,988,353

99.21%

1,599,886

0.79%

0

10

Reappointment of Ali Al Husry

199,090,927

98.76%

2,497,312

1.24%

0

11

Reappointment of Michael Ashton

196,521,848

98.45%

3,095,916

1.55%

1,970,475

12

Reappointment of Ronald Goode

198,210,008

99.05%

1,901,133

0.95%

1,477,098

13

Reappointment of Patrick Butler

200,562,012

99.49%

1,026,227

0.51%

0

14

Reappointment of Dr Pamela Kirby

199,880,568

99.15%

1,707,671

0.85%

0

15

Approve the 2015 remuneration implementation

173,423,087

88.97%

21,510,812

11.03%

6,654,338

16

Authorise the directors to allot shares

176,261,935

87.65%

24,841,433

12.35%

484,894

17

Disapply pre-emption rights

179,904,929

90.65%

18,558,726

9.35%

3,124,607

18

Authorise the company to buy back shares

200,673,199

99.55%

915,063

0.45%

0

19

Authorise the company to call general meetings on 14 days' notice

185,097,715

91.88%

16,365,074

8.12%

125,473

 

Declaration of final dividend

The dividend of 21 cents per share will be paid on 19 May 2016 to shareholders on the register on 8 April 2016.  Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling.  The exchange rate in respect of this dividend will be $1.4510 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at 1JD to $1.4104.

- ENDS -

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Peter Speirs

Company Secretary

 

+44 20 7399 2670

Susan Ringdal

VP for Investor Relations and Strategy

 

+44 20 7399 2670

 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million. 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGSFFFLEFMSEFI
UK 100

Latest directors dealings